FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

Part of paid clinical trials in New York, New York.

Sponsor
Icahn School of Medicine at Mount Sinai
Study ID
NCT03718923
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
2 Years - N/A
Healthy Volunteers
Not accepted

Study Details

FOXP1, also known as Forkhead-box Protein P1, is a transcription factor protein belonging to the FOX gene family. Disruptions in the FOXP1 gene cause a phenotype characterized by global developmental delay, speech deficits, mild dysmorphic features, and traits of autism spectrum disorder. This study seeks to characterize FOXP1-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.

Key Dates

Start date
Mar 28, 2016
Status verified
May 2026
Primary completion
May 31, 2028
Completion
May 31, 2028

Study Design

Enrollment
50 participants (estimated)

Primary Outcome Measure

Autism Diagnostic Observation Schedule (ADOS) [ Time Frame: Day 1 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The Seaver Autism Center for Research and TreatmentNew YorkNew York10029
Bonnie Lerman, B.S.
[email protected]
(212) 241- 2995
Samantha Bright, B.A.
[email protected]
212-241-0961

Find similar trials in New York, NY

By condition
Autism spectrum disorder
By specialty
Pediatrics
By research site
The Seaver Autism Center for Research and Treatment· New York, NY

Related Studies